MarketCap
Viridian Therapeutics VRDN
$ 28.53
-1.76%
Facebook
X
Telegram
Country |
 USA |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
102 M |
Market Cap[1] |
$ 2.91 B |
EBITDA (LTM) |
$ -468 M |
P/E (LTM) |
- |
P/S (LTM) |
112.396578 |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Viking Therapeutics
VKTX
|
$ 25.78 | -7.83 % | $ 2.9 B | Nasdaq Capital Market | USA |
 |
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.08 | -10.85 % | $ 32.8 M | Nasdaq Global Market | USA |
 |
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | USA |
 |
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | USA |
 |
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | USA |
 |
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | USA |
 |
Immunome
IMNM
|
$ 17.86 | -8.5 % | $ 1.56 B | Nasdaq Global Select Market | USA |
 |
Immuron Limited
IMRN
|
$ 0.85 | -0.01 % | $ 196 M | Nasdaq Global Select Market |  Australia |
 |
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market |  Canada |
 |
Immunic
IMUX
|
$ 7.44 | -6.3 % | $ 1.16 B | Nasdaq Global Select Market | USA |
 |
Incyte Corporation
INCY
|
$ 118.15 | -3.83 % | $ 23.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.0 | -0.99 % | $ 11.3 M | Nasdaq Capital Market | USA |
 |
Atea Pharmaceuticals
AVIR
|
$ 4.2 | -5.83 % | $ 342 M | Nasdaq Global Select Market | USA |
 |
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | USA |
 |
INmune Bio
INMB
|
$ 1.18 | -11.14 % | $ 29.2 M | Nasdaq Capital Market | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | Canada |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
X4 Pharmaceuticals
XFOR
|
$ 3.06 | -5.56 % | $ 129 M | Nasdaq Capital Market | USA |
 |
Xencor
XNCR
|
$ 34.0 | -2.94 % | $ 2.52 B | Nasdaq Global Select Market,SPB | USA |
 |
Jounce Therapeutics
JNCE
|
- | - | $ 98.4 M | Nasdaq Global Select Market | USA |
 |
Verona Pharma plc
VRNA
|
- | - | $ 69.7 B | Nasdaq Global Select Market |  Britain |
 |
Zai Lab Limited
ZLAB
|
$ 22.61 | -0.83 % | $ 24.8 B | Nasdaq Global Select Market |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 1.72 | -2.56 % | $ 124 M | Nasdaq Global Market | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
- | -0.89 % | $ 114 M | Nasdaq Global Select Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 38.76 | -3.46 % | $ 6.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 7.66 | -17.55 % | $ 516 B | Nasdaq Capital Market | Britain |
 |
Mersana Therapeutics
MRSN
|
- | - | $ 3.56 B | Nasdaq Global Select Market | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
- | - | $ 384 M | Nasdaq Global Select Market | Britain |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Timber Pharmaceuticals
TMBR
|
- | - | $ 717 K | NYSE American | USA |
 |
G1 Therapeutics
GTHX
|
- | - | $ 370 M | Nasdaq Global Select Market,SPB | USA |
 |
Amryt Pharma plc
AMYT
|
- | - | $ 621 M | Nasdaq Global Select Market | Britain |
 |
Kinnate Biopharma
KNTE
|
- | - | $ 123 M | Nasdaq Global Select Market | USA |
|
Cerevel Therapeutics Holdings
CERE
|
- | - | $ 7.29 B | Nasdaq Capital Market | USA |
 |
NexImmune
NEXI
|
- | 70.13 % | $ 4.12 M | Nasdaq Global Market | USA |
 |
Theravance Biopharma
TBPH
|
$ 17.03 | 0.03 % | $ 857 M | Nasdaq Global Select Market |  Cayman-islands |
 |
Axon Enterprise
AXON
|
$ 379.58 | -10.52 % | $ 29.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Axsome Therapeutics
AXSM
|
$ 129.19 | -5.7 % | $ 6.43 B | Nasdaq Global Market,SPB | USA |
 |
IMV
IMV
|
- | - | $ 13.1 M | Nasdaq Global Select Market | Canada |
 |
Karuna Therapeutics
KRTX
|
- | - | $ 12.2 B | Nasdaq Global Market,SPB | USA |
 |
Chimerix
CMRX
|
- | - | $ 756 M | Nasdaq Global Select Market | USA |
 |
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | USA |
 |
LogicBio Therapeutics
LOGC
|
- | - | $ 229 M | Nasdaq Global Market | USA |
|
89bio
ETNB
|
- | - | $ 1.55 B | Nasdaq Global Market | USA |
 |
Merck & Co.
MRK
|
$ 146.9 | -2.29 % | $ 368 B | NYSE,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.